Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab vs Eculizumab in PNH (CHAMPION 302)
NCT03056040Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- May 2017
- Primary completion
- Feb 2022
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 3 trial of ravulizumab in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Alexion Pharmaceuticals. Started May 2017; status: completed.
02
Drugs
ravulizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT03056040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03056040.